In addition, there are crucial questions about the main candidate vaccines that remain unanswered . Political and economic pressures in high-income countries mean that pharmaceutical companies are trying to speed up the approval of their mobile phone number list vaccines. That's why they've designed their phase III clinical trials to get positive results as soon as possible, instead of answering big questions ., for example if the vaccine prevents contagion mobile phone number list or only protects against the disease.
The duration of protection is also unclear; whether the vaccine is equally effective in the young and the elderly, or in people with comorbidities; and what differences there are between the main candidates (which is essential for the design of effective mobile phone number list vaccination strategies). Furthermore, the process of distributing vaccines continues to be dominated by national interests (particularly those of developed countries). Although the Global Access Fund for Covid-19 Vaccines ( COVAX) is a great advance, it loses effectiveness mobile phone number list in the face of huge bilateral advance purchase agreements from rich countries that can afford to bet on several vaccines.
For example, high-income countries have already mobile phone number list purchased about 80% of the Pfizer/BioNTech and Moderna vaccine doses that are available in the first year. In short, rich countries have appropriated 3.8 billion doses from different manufacturers, against 3.2 billion (including some 700 million doses for COVAX) for the rest of the world. In other words, they reserved enough doses to cover their populations several times, with the possibility that the remaining doses will not be enough to vaccinate even the most vulnerable groups in other countries.